Alzheimer's drug extension study halted after 12 patients
NCT ID NCT06833281
Summary
This study aimed to test the long-term safety and effectiveness of an oral medication called SPG302 for people with mild-to-moderate Alzheimer's disease. It was an extension of a previous trial, allowing participants to continue taking the drug for up to one year while monitoring side effects and changes in memory and daily function. The study was terminated after enrolling only 12 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Flinders Medical Center
Adelaide, South Australia, 5000, Australia
-
St. Vincent's Hospital
Sydney, New South Wales, 2010, Australia
Conditions
Explore the condition pages connected to this study.